GILEAD (GILD) Tmuɣli n wazal
Gilead Sciences
Ṛṛbem n lḥedd$150.95Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel+0.90%
Asnulfu n AI: GILD
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Gilead Sciences, Inc. is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic agents to improve care for patients with life-threatening diseases. The company’s key areas of focus include HIV, AIDS, liver diseases, and serious cardiovascular and respiratory conditions.
